NVS
HEALTHCARENovartis AG
$148.36+2.86 (+1.97%)PRE
Live · NYSE · May 8, Close
AI Insight
What's Moving NVS Today?
No stock-specific AI insight has been generated for NVS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$101.83$165.43
$148.36
Fundamentals
Market Cap$283.1B
P/E Ratio21.3
EPS$6.97
Dividend Yield0.03%
Dividend / Share$4.67
ROE0.3%
Profit Margin0.2%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding1.91B
NVS News
48 articles- Construction begins on Novartis’ RLT centre in Texas, USPharmaceutical-technology·May 8, 2026
- DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion pushYahoo Finance·May 7, 2026
- Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilitiesYahoo Finance·May 7, 2026
- Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesYahoo Finance·May 7, 2026
- This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A BreakoutYahoo Finance·May 6, 2026
- Novartis Weighs US Buildout And Rhapsido Launch In Growth OutlookYahoo Finance·May 6, 2026
- European Bond Market Has Record Day as Rates Outlook WorsensYahoo Finance·May 6, 2026
- Medable CEO Michelle Longmire Featured as Guest Speaker with Leaders from Google and Mayo Clinic at Japan’s Largest Pharmaceutical SummitYahoo Finance·May 6, 2026
- Thyroid Cancer (TC) Market View Report 2026: Ipsen/Exelixis, Ono Pharmaceutical, and Novartis Dominate the Treatment LandscapeYahoo Finance·May 6, 2026
- Model N Appoints Thomas Gibbs to Board of DirectorsYahoo Finance·May 5, 2026
- Faron Pharmaceuticals Ltd: Directorate AppointmentYahoo Finance·May 5, 2026
- Celcuity strengthens case for ASCO-spotlighted breast cancer drugBiopharmadive·May 4, 2026
- Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3GYahoo Finance·May 1, 2026
- Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y GrowthYahoo Finance·May 1, 2026
- Here's What Analysts Are Forecasting For Novartis AG (VTX:NOVN) After Its First-Quarter ResultsYahoo Finance·May 1, 2026
- PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis MilestoneYahoo Finance·Apr 30, 2026
- Novartis finalizes US manufacturing and R&D expansion plan with seventh new facilityYahoo Finance·Apr 30, 2026
- Novartis Reshapes Growth With Biotech Deals And AI Powered R&D PushYahoo Finance·Apr 30, 2026
- Novartis Expands R&D Spending Up To $70 Million Monthly After Avidity DealYahoo Finance·Apr 29, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc.·Apr 28, 2026
- Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor IntelligenceGlobeNewswire Inc.·Apr 28, 2026
- Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and GaldermaGlobeNewswire Inc.·Apr 23, 2026
- Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & OutlookGlobeNewswire Inc.·Apr 21, 2026
- Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightGlobeNewswire Inc.·Apr 20, 2026
- Better Pharma Dividend Stock: Novartis vs. MerckThe Motley Fool·Apr 17, 2026
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
- What if you could reboot sick cells?GlobeNewswire Inc.·Apr 15, 2026
- $5.14 Bn Castration-sensitive Prostate Cancer Market Insights, Epidemiology, and Forecasts, 2022-2026 & 2026-2036GlobeNewswire Inc.·Apr 13, 2026
- 7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing TreatmentsGlobeNewswire Inc.·Apr 10, 2026
- Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data ReviewBenzinga·Apr 7, 2026
- Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a DimeInvesting.com·Apr 6, 2026
- Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsightGlobeNewswire Inc.·Apr 1, 2026
- Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and MoreGlobeNewswire Inc.·Apr 1, 2026
- Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney HealthGlobeNewswire Inc.·Mar 30, 2026
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)GlobeNewswire Inc.·Mar 30, 2026
- Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)GlobeNewswire Inc.·Mar 30, 2026
- Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab)GlobeNewswire Inc.·Mar 30, 2026
- Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. DominateGlobeNewswire Inc.·Mar 30, 2026
Price Data
Open$143.05
Previous Close$145.50
Day High$144.04
Day Low$142.25
52 Week High$165.43
52 Week Low$101.83
52-Week Range
$101.83$165.43
$148.36
Fundamentals
Market Cap$283.1B
P/E Ratio21.3
EPS$6.97
Dividend Yield0.03%
Dividend / Share$4.67
ROE0.3%
Profit Margin0.2%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding1.91B
About Novartis AG
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—